Skip to main content

Table 2 Univariate and multivariate analyses of prognostic factors with RFS and OS in patients with HCC (n = 95)

From: Tumor–stroma ratio predicts prognosis and PD-L1 expression in hepatocellular carcinoma

Clinicopathologic variable

RFS

OS

HR (95% CI)

P-value

HR (95% CI)

P-value

Univariate analysis

 Gender (male vs. female)

1.38 (0.28–6.81)

0.69

2.04 (0.53–7.84)

0.30

 Age, years (> 60 vs. ≤ 60)

1.02 (0.98–1.07)

0.32

1.02 (0.98–1.06)

0.40

 Serum albumin, g/L (≤ 35 vs. > 35)

1.03 (0.93–1.14)

0.61

1.02 (0.94–1.10)

0.68

 Platelet,10^9/L (≤ 160 vs. > 160)

0.997 (0.99–1.004)

0.12

1.001 (0.996–1.01)

0.63

 ALT, U/L (≤ 50 vs. > 50)

0.98 (0.981–1.007)

0.35

0.994 (0.978–1.01)

0.44

 AST, U/L (≤ 40 vs. > 40)

0.994 (0.99–1.03)

0.29

1.004 (0.99–1.017)

0.59

 PT, s (≤ 13.2 vs. > 13.2)

0.64 (0.40–1.02)

0.06

0.82 (0.57–1.17)

0.27

 AFP, ng/mL (> 20 vs. ≤ 20)

3.84 (0.81–18.14)

0.09

1.11 (0.44–2.85)

0.82

 HBV (presence vs. absence)

2.96 (0.36–24.37)

0.31

1.78 (0.56–5.69)

0.33

 TSR (> high vs. ≤ low)

1.16 (0.34–4.06)

0.82

3.33 (1.03–10.73)

0.04

 BCLC stage (C vs. 0/A/B)

1.78 (0.46–6.84)

0.40

4.93 (1.35–18.02)

0.02

 TNM stage (II/III vs. I)

4.75 (0.59–38.36)

0.14

3.19 (0.86–11.87)

0.08

 Tumor number (multiple vs. single)

1.44 (0.44–4.65)

0.55

1.53 (0.54–4.36)

0.42

 Edmondson grade (III/IV vs. I/II)

1.16 (0.34–3.98)

0.82

1.21 (0.47–3.15)

0.70

 Tumor size, cm (> 5 vs. ≤ 5)

1.13 (0.95–1.34)

0.17

1.33 (1.13–1.58)

0.01

 Satellite nodules (presence vs. absence)

1.27 (0.24–6.62)

0.78

4.66 (0.56–38.6)

0.15

 Tumor encapsulation (none vs. complete)

1.56 (0.51–4.79)

0.44

1.04 (0.40–2.67)

0.94

 Liver cirrhosis (presence vs. absence)

3.84 (0.81–18.14)

0.09

1.41 (0.54–3.67)

0.49

 CTP (A vs. B)

2.69 (0.32–22.28)

0.36

6.57 (0.81–53.07)

0.08

Multivariate analysis

 PT, s (≤ 13.2 vs. > 13.2)

0.91 (0.76–1.10)

0.34

NA

 

 CTP (A vs. B)

NA

 

1.11 (0.52–2.37)

0.79

 AFP, ng/mL (> 20 vs. ≤ 20)

1.29 (0.79–2.09)

0.31

1.13 (0.67–1.94)

0.63

 Tumor size, cm (> 5 vs. ≤ 5)

1.00 (0.92–1.08)

0.35

1.05 (0.97–1.14)

0.23

 TSR (> high vs. ≤ low)

10.06 (1.61–63.03)

0.02

8.34 (1.18–59.48)

0.03

 BCLC (C vs. 0/A/B)

NA

 

2.28 (1.08–4.82)

0.31

 TNM (II/III vs. I)

1.89 (0.92–3.88)

0.81

1.01 (0.44–2.32)

0.97

 Liver cirrhosis (presence vs. absence)

1.12 (0.68–1.83)

0.65

1.14 (0.66–1.95)

0.63

  1. HBsAg Hepatitis B surface antigen, AFP α-fetoprotein, TNM Tumor-node-metastasis, PT Prothrombin time, CTP Child-Turcotte-Pugh, BCLC stage The Barcelona Clinic Liver Cancer staging, ALT Glutamic-pyruvic transaminase, AST Glutamic oxalacetic transaminase